Abstract Announcements and Exceptions

According to ASCO's Abstract Policy, abstracts submitted to the Gastrointestinal Cancers Symposium are confidential from the time of submission until the specified embargo lift date and time when the data becomes publicly available. Under extenuating circumstances, ASCO may grant a formal exception to its Abstract Policy. Abstract Policy Exceptions require advance approval by ASCO before the information is made public.

ASCO has granted formal Policy Exceptions for the following abstracts to allow limited information to be made publicly available in advance of the Gastrointestinal Cancers Symposium due to Securities and Exchange Commission (SEC) requirements:

Abstract #613

Phase I study of biweekly liposome irinotecan (PEP02, MM-398) in metastatic colorectal cancer failed on first-line oxaliplatin-based chemotherapy.